AllPeptides.eu - Advanced Peptide Research
    Single Peptides
    Anti_aging

    NAD+ (500mg)

    Subcutaneous injection3× weekly500mg

    Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16

    🇺🇸 GRAS

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    Research-only — no FDA/EMA approval
    Educational information. Not medical advice or a recommendation for use.

    ⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer

    Available sizes:
    500mg
    250mg
    1000mg

    Research monograph

    See the full NAD+ encyclopedia page with mechanism, evidence tier, related variants and research context.

    Open monograph
    Free Access

    How It Works

    NAD+ is essential for mitochondrial ATP production, DNA repair via PARP, and sirtuin activation. Supplementation reverses aspects of cellular aging.

    Quick Start

    • Typical dose: 50–100 mg subcutaneously, 3× weekly.
    • Frequency: 3×/week (e.g. Mon/Wed/Fri)
    • Storage: 2–8°C after reconstitution
    Detailed Protocol Data

    Dosing Table — NAD+ 500mg

    Educational only
    Vial Size— affects syringe units
    BAC Water5 mL
    Concentration100.00 mg/mL

    Route: Subcutaneous injection | Frequency: 3× weekly

    WeekDoseUnits (per injection)
    Weeks 1–2
    50 mg
    50 Units (0.50 mL)
    Weeks 3–8
    100 mg
    100 Units (1.00 mL)

    Subcutaneous administration 3 times weekly (e.g. Mon/Wed/Fri): 50 mg in weeks 1–2, then 100 mg. The injection may cause transient stinging — inject slowly. There is no clinical protocol for subcutaneous NAD+; this schedule reflects reported practice.

    Related compounds

    Reconstitution Steps

    1. Clean vial stoppers with an alcohol swab.
    2. Draw up 5mL of bacteriostatic water.
    3. Slowly inject into the vial wall.
    4. Gently swirl until fully dissolved.
    5. Store refrigerated (2–8°C).

    Protocol Overview

    • NAD+ declines with age — replenishment supports cellular energy and DNA repair.
    • Activates sirtuins (SIRT1-7), key regulators of aging.
    • Supports mitochondrial function and metabolism.

    Dosing Protocol

    • Start: 50 mg 3×/wk (Wks 1–2).
    • Maintenance: 100 mg 3×/wk (Wks 3–8).
    • Weekly amount: 150 mg (Wks 1–2) → 300 mg.
    • Cycle: 4–8 weeks, subcutaneous only.
    • Break between cycles: After 4–8 weeks, a 4-week pause before the next cycle.

    Washout & Cycle Restart

    When can I restart?

    After 4–8 weeks, a 4-week pause before the next cycle.

    Minimum wait period: 4 weeks

    Storage Instructions

    • Reconstituted: 2–8°C, use within 21 days.
    • Powder: 2-8°C or -20°C long-term.

    Important Notes

    • Stinging during injection is normal—decreases with slow administration.
    • Avoid late-night injections (may disrupt sleep).
    • Combines well with TMG (trimethylglycine) for methyl group support.
    Clinical Analysis & Safety

    Potential Benefits & Side Effects

    Potential Benefits:

    • Increased cellular energy
    • Enhanced DNA repair
    • Anti-aging via sirtuins
    • Improved neurological function
    • Mitochondrial health support

    Potential Side Effects:

    • Injection site stinging/soreness
    • Nausea (at high doses)
    • Sleep disturbance (if injected late)
    • Flushing

    ⚠️ Serious Warnings & Long-Term Risks

    The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.

    🎗️ Cancer Markers
    🟡 Moderate / Theoretical

    Metabolism enhancement — potential tumor protection

    NAD+ elevation may theoretically benefit cancer cells by enhancing their energy metabolism (Warburg effect). Some studies show that NAMPT inhibition (NAD synthesis enzyme) suppresses oncogenesis.

    📄 Cancer Cell 2018; Nat Rev Cancer 2020
    ⚠️ Other
    🟡 Moderate / Theoretical

    Flushing & GI discomfort with IV administration

    IV NAD+ commonly causes chest tightness, flushing, nausea, cramps. Subcutaneous administration reduces these but with local pain.

    📄 GeroScience 2023

    References

    1. NAD+ and Aging — Yoshino J, et al. NAD+ intermediates: the biology and therapeutic potential. Cell Metab. 2018;27(3):513-528.
      View Source
    2. Sirtuins and NAD+ — Imai S, Guarente L. NAD+ and sirtuins in aging. Trends Cell Biol. 2014;24(8):464-471.
      View Source

    Recommended Supplements

    Research Sources & Verified Data
    …
    Clinical Trials
    …
    PubMed Studies
    Research-only
    FDA Status
    0
    Regulatory Approvals
    Verified across ClinicalTrials.gov, PubMed & FDA

    External Sources & Regulatory Status

    Regulatory Approvals

    🇺🇸
    FDA
    GRAS

    Dietary supplement (GRAS)

    Dietary supplement (GRAS)

    No official regulatory source available yet — research peptide.

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    Summary:
    1 Approvals
    0 PubMed
    0 Clinical Studies

    Continue Your Research

    Explore tools and guides related to this protocol.

    Educational contentRegularly reviewed & maintainedEvidence-based review

    Important Disclaimer

    The content of this website is provided exclusively for informational and educational purposes within the context of research literature.

    Read the full Disclaimer →

    Educational Navigator

    Educational reading navigator

    Find where to start in research peptide science through evidence, safety context and regulatory awareness.

    Covers

    Evidence levelsSafety contextRegulatory overviewLiterature readingResearch methodEducational reports
    5 min readEvidence-firstOpen access
    Open evidence framework

    New knowledge, new tools and selected updates from AllPeptides.eu